RET-rearranged NSCLC patients were included in this study based on pre-clinical evidence that erdafitinib, a small molecular kinase inhibitor, displayed high selectivity with a binding affinity of 1.88 nM to RET, lower than the binding affinity with the four different members of FGFR (unpublished data). Here, RET is linked to non-small cell lung carcinoma.